Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

TGTX
TG Therapeutics, Inc.
stock NASDAQ

At Close
Jun 6, 2025 3:59:49 PM EDT
40.07USD+1.959%(+0.77)2,135,741
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jun 6, 2025 9:28:30 AM EDT
39.88USD+1.476%(+0.58)2,778
After-hours
Jun 6, 2025 4:00:30 PM EDT
40.06USD+0.050%(+0.02)3,982
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 28, 2022
10:54AM EST  TG Therapeutics Option Alert: Feb 18 $12 Calls at the Ask: 1206 @ $0.25 vs 276 OI; Earnings 3/1 Before Open [est] Ref=$9.15   Benzinga
06:15AM EST  HC Wainwright & Co. Maintains Buy on TG Therapeutics, Lowers Price Target to $68   Benzinga
Jan 27, 2022
10:33AM EST  TG Therapeutics Earlier Disclosed FDA Imposed Partial Clinical Hold On Select Studies Of U2 And Its Components For CLL And NHL   Benzinga
Jan 24, 2022
12:04PM EST  Where TG Therapeutics Stands With Analysts   Benzinga
07:39AM EST  10 Biggest Price Target Changes For Monday   Benzinga
07:30AM EST  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Companys Chairman and Chief Executive Officer, will participate in a fireside chat during the B. Riley Securities 2022 Virtual Oncology Investor Conference, taking place on Thursday, January 27, 2022, at 10:00 AM ET.   GlobeNewswire Inc
04:30AM EST  HC Wainwright & Co. Maintains Buy on TG Therapeutics, Lowers Price Target to $70   Benzinga
Jan 5, 2022
07:30AM EST  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Companys Chairman and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday January 10, 2022 at 9:45 AM ET.   GlobeNewswire Inc
Jan 4, 2022
07:30AM EST  TG Therapeutics Expands Term Loan Facility With Hercules Capital   GlobeNewswire Inc
Dec 27, 2021
09:00PM EST  TG THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is   GlobeNewswire Inc
Dec 14, 2021
07:32AM EST  TG Therapeutics Highlights ASH Presentation   Benzinga
07:30AM EST  TG Therapeutics Announces Data from the UNITY-CLL Phase 3 Trial   GlobeNewswire Inc
07:29AM EST  TG Therapeutics Announces FDA Acceptance Of BLA For Ublituximab As A Treatment ForRelapsing Forms Of Multiple Sclerosis   RTTNews
07:24AM EST  TG Therapeutics Announces FDA Acceptance Of Biologics License Application For Ublituximab As A Treatment For Patients With Relapsing Forms Of Multiple Sclerosis   Benzinga
07:15AM EST  Prescription Drug User Fee Act (PDUFA) goal date of September 28, 2022   GlobeNewswire Inc
Dec 13, 2021
07:39AM EST  TG Therapeutics Announces Data Presentations At The 63rd American Society Of Hematology Annual Meeting   Benzinga
07:30AM EST  TG Therapeutics Announces Data Presentations at the 63rd American   GlobeNewswire Inc
Dec 10, 2021
07:36AM EST  TG Therapeutics Recaps Schedule Of Data Presentations At American Society Of Hematology Meeting Dec. 11-13   Benzinga
07:30AM EST  TG Therapeutics, Inc. (NASDAQ: TGTX), today recapped the schedule of data presentations at the upcoming 63rd American Society of Hematology (ASH) annual meeting and exposition, to be held December 11 14, 2021, virtually and also live at the Georgia World Congress Center in Atlanta, Georgia.   GlobeNewswire Inc
Dec 2, 2021
10:02PM EST  TG THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is   GlobeNewswire Inc
Dec 1, 2021
09:23AM EST  Evercore ISI Group Maintains Outperform on TG Therapeutics, Lowers Price Target to $36   Benzinga
08:12AM EST  10 Biggest Price Target Changes For Wednesday   Benzinga
07:37AM EST  Goldman Sachs Maintains Sell on TG Therapeutics, Lowers Price Target to $13   Benzinga
06:28AM EST  HC Wainwright & Co. Maintains Buy on TG Therapeutics, Lowers Price Target to $75   Benzinga
Nov 30, 2021
05:34PM EST  Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. (TG Therapeutics or the Company) (NASDAQ: TGTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
05:00PM EST  Mid-Afternoon Market Update: Dow Dips 500 Points; ImmunoGen Shares Spike Higher   Benzinga
04:56PM EST  Mid-Day Market Update: Barnes & Noble Education Drops Following Q2 Results; Cumberland Pharmaceuticals Shares Jump   Benzinga
04:53PM EST  Why TG Therapeutics Stock Is Falling Today   Benzinga
04:52PM EST  Mid-Morning Market Update: Markets Mostly Lower; JinkoSolar Issues Weak Sales Forecast   Benzinga
04:44PM EST  TG Therapeutics Announces FDA Has Notified Co. It Plans To Host Meeting Of The Oncologic Drugs Advisory Committee In Connection To Biologics License Application For ublituximab And UKONIQ Combination   Benzinga
07:30AM EST  TG Therapeutics Provides Regulatory Update   GlobeNewswire Inc
Nov 15, 2021
11:20AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 15, 2021   Benzinga
10:46AM EST  Goldman Sachs Downgrades TG Therapeutics to Sell, Lowers Price Target to $26   Benzinga
07:30AM EST  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Companys Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the Jefferies London Healthcare Conference, taking place virtually November 18 19, 2021.   GlobeNewswire Inc
Nov 9, 2021
07:30AM EST  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Companys Chairman and Chief Executive Officer, will participate in a fireside chat during the B. Riley Securities Fall 2021 Growth Biotech Best Ideas Virtual Series, taking place on Thursday November 11, 2021, at 12:00 PM ET.   GlobeNewswire Inc
Nov 4, 2021
09:38AM EDT  TG Therapeutics Highlights Data Selected For Presentation At The 63rd American Society Of Hematology Annual Meeting   Benzinga
07:59AM EDT  TG Therapeutics Q3 EPS $(0.65) Misses $(0.56) Estimate, Sales $2.03M Miss $2.97M Estimate   Benzinga
07:00AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2021 and recent company developments, along with a business outlook for the remainder of 2021.   GlobeNewswire Inc
05:00AM EDT  Earnings Scheduled For November 4, 2021   Benzinga
Nov 1, 2021
07:30AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Thursday, November 4, 2021 at 8:30 AM ET to discuss results for the third quarter 2021 and provide a business outlook for the remainder of the year. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.   GlobeNewswire Inc
Oct 14, 2021
10:49AM EDT  TG Therapeutics Highlights Presentation Of Ublituximab Data At 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis   Benzinga
10:45AM EDT  New ULTIMATE I & II data presented at ECTRIMS shows ublituximab treatment is associated with significant improvement in the multiple sclerosis functional composite (MSFC) score   GlobeNewswire Inc
Sep 30, 2021
07:36AM EDT  TG Therapeutics Submits Biologics License Application To The U.S. FDA For Ublituximab As A Treatment For Patients With Relapsing Forms Of Multiple Sclerosis   Benzinga
07:35AM EDT  TG Therapeutics Submits BLA For Ublituximab For Relapsing Forms Of Multiple Sclerosis   RTTNews
07:30AM EDT  TG Therapeutics Submits Biologics License Application to the U.S.   GlobeNewswire Inc
Sep 29, 2021
07:36AM EDT  TG Therapeutics Announces Data Presentations From ULTIMATE I & II Phase 3 Trials Of Ublituximab In Multiple Sclerosis To Be Presented At 37th Congress Of The European Committee For Treatment And Research In Multiple Sclerosis   Benzinga
07:30AM EDT  The ULTIMATE I & II Phase 3 trials both have met their primary endpoint with ublituximab treatment demonstrating a statistically significant reduction in annualized relapse rate (ARR) over a 96-week period (p<0.005 in each trial)   GlobeNewswire Inc
Sep 23, 2021
08:08AM EDT  TG Therapeutics Highlights Publication Of Results From Integrated Safety Analysis Of UKONIQ In Blood Advances   Benzinga
08:00AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of results from an integrated safety analysis of UKONIQ(umbralisib), the Companys inhibitor of PI3k-delta and CK1-epsilon, in patients with relapsed or refractory lymphoid malignancies in Blood Advances, ajournal of the American Society of Hematology.   GlobeNewswire Inc
07:37AM EDT  TG Therapeutics To Participate In 2021 Cantor Virtual Global Healthcare Conference Sept. 27   Benzinga
07:30AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Companys Chairman and Chief Executive Officer, will participate in a fireside chat during the 2021 Cantor Virtual Healthcare Conference, taking place September 27 30, 2021. The fireside chat is scheduled to take place on Monday, September 27, 2021 at 10:40 AM ET.   GlobeNewswire Inc
Sep 20, 2021
07:35AM EDT  TG Therapeutics Announces Combination Data Presentations At The XIX International Workshop On Chronic Lymphocytic Leukemia   Benzinga
07:30AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL). Data highlights from each presentation are included below.   GlobeNewswire Inc
Sep 19, 2021
09:46AM EDT  The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions and Conference Presentations In The Spotlight   Benzinga
Sep 17, 2021
07:36AM EDT  The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold   Benzinga
Sep 13, 2021
09:21AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX), today recapped the schedule of upcoming data presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL), being held virtually September 17 20, 2021. Full text abstracts are now available through the iwCLL virtual platform, and details of the upcoming data presentations are below.   GlobeNewswire Inc
Sep 12, 2021
04:04PM EDT  The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs   Benzinga
Sep 9, 2021
09:00AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Companys Chairman and Chief Executive Officer, will participate in a fireside chat during the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13 15, 2021.   GlobeNewswire Inc
Aug 30, 2021
07:32AM EDT  TG Therapeutics Announces Data Presentations At Upcoming XIX International Workshop On Chronic Lymphocytic Leukemia Sept. 17-20   Benzinga
07:30AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of four data presentations at the upcoming XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL), being held virtually September 17 20, 2021. Details of the data presentations are included below.   GlobeNewswire Inc
Aug 13, 2021
10:50AM EDT  Looking into TG Therapeutics's Return on Capital Employed   Benzinga
Aug 2, 2021
02:50PM EDT  Mid-Afternoon Market Update: Nasdaq Gains 50 Points; Marin Software Shares Plummet   Benzinga
12:52PM EDT  HC Wainwright & Co. Maintains Buy on TG Therapeutics, Lowers Price Target to $84   Benzinga
12:07PM EDT  Mid-Day Market Update: Crude Oil Down 2.5%; Exicure Shares Spike Higher   Benzinga
10:12AM EDT  Mid-Morning Market Update: Markets Open Higher; Global Payments Posts Upbeat Q2 Earnings   Benzinga
09:53AM EDT  Shares of TG Therapeutics Inc. (TGTX) are losing nearly 12% on Monday morning after the company's second-quarter results missed Wall Street estimates.   RTTNews
07:10AM EDT  TG Therapeutics Q2 EPS $(0.59) Misses $(0.50) Estimate, Sales $1.54M Up From $38.00K YoY   Benzinga
07:00AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ending June 30, 2021 and recent company developments, along with a business outlook for the remainder 2021.   GlobeNewswire Inc
04:05AM EDT  Earnings Scheduled For August 2, 2021   Benzinga
Jul 28, 2021
07:30AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, August 2, 2021 at 8:30 AM ET to discuss results for the second quarter 2021 and provide a business outlook for the remainder of the year. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.   GlobeNewswire Inc
Jul 9, 2021
07:30AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Companys Chairman and Chief Executive Officer, will participate in a fireside chat during the Ladenburg Thalmann 2021 Healthcare Conference being held virtually. The fireside chat is scheduled to take place on Wednesday, July 14, 2021 at 12:30 PM ET.   GlobeNewswire Inc
Jun 29, 2021
07:30AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced with great sadness the passing of longtime Board Member, William J. Kennedy, PhD.   GlobeNewswire Inc
Jun 23, 2021
10:48AM EDT  Looking Into TG Therapeutics's Return On Capital Employed   Benzinga
Jun 18, 2021
02:00PM EDT  TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of Neurology   Benzinga
02:00PM EDT  TG Therapeutics Announces Presentation of Data from the ULTIMATE I   GlobeNewswire Inc
07:41AM EDT  TG Therapeutics Announces Data From Two Presentations Evaluating TG-1701   RTTNews
07:36AM EDT  TG Therapeutics Highlights Presentation Of TG-1701 Data At International Congress On Malignant Lymphoma   Benzinga
07:35AM EDT  TG Therapeutics Announces Preclinical and Clinical Data Evaluating   GlobeNewswire Inc
Jun 11, 2021
07:01AM EDT  TG Therapeutics Reports Data From Phase 1 Study Of TG-1701 As Monotherapy, Triple Combo With Ublituximab, UKONIQ At European Hematology Association Virtual Congress   Benzinga
07:00AM EDT  TG Therapeutics Announces Data from a Phase 1 Study Evaluating   GlobeNewswire Inc
Jun 9, 2021
07:06AM EDT  TG Therapeutics To Present At 16th International Congress on Malignant Lymphoma Jun. 18-22   Benzinga
07:00AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 16th International Congress on Malignant Lymphoma (ICML), being held virtually June 18 22, 2021. Details of the data presentations are included below.   GlobeNewswire Inc
Jun 7, 2021
10:01AM EDT  Return On Capital Employed Overview: TG Therapeutics   Benzinga
Jun 4, 2021
09:12AM EDT  TG Therapeutics Announces Data From Phase 1 Study Evaluating TG-1701 As A Monotherapy And As A Triple Combination With Ublituximab And UKONIQ At 2021 ASCO Meeting   Benzinga
09:00AM EDT  100% ORR in CLL patients treated with 300 mg QD of TG-1701 monotherapy (n=19)   GlobeNewswire Inc
May 27, 2021
07:30AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its participation at three upcoming virtual investor conferences. Michael S. Weiss, the Companys Executive Chairman and Chief Executive Officer, is scheduled to participate in the following:   GlobeNewswire Inc
May 25, 2021
11:30AM EDT  TG Therapeutics shares were trading higher after the company announced FDA acceptance of the Biologics License Application for ublituximab in combination with UKONIQ as a treatment for patients with CLL and SLL.   Benzinga
11:08AM EDT  TG Therapeutics' Ublituximab-Umbralisib Combo Application Under FDA Review for Hematological Malignancies   Benzinga
07:11AM EDT  TG Therapeutics Says FDA Accepted BLA For Ublituximab In Combination With UKONIQ   RTTNews
07:01AM EDT  TG Therapeutics Announces FDA Acceptance Of Biologics License Application For Ublituximab In Combination With UKONIQ As Treatment For Patients With Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma   Benzinga
07:00AM EDT  TG Therapeutics Announces FDA Acceptance of Biologics License   GlobeNewswire Inc
May 13, 2021
07:30AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the American Society of Clinical Oncology (ASCO) annual meeting, to be held virtually June 4 8, 2021 and the European Hematology Association (EHA) annual congress, to be held virtually June 9 17, 2021. Details of the data presentations are included below.   GlobeNewswire Inc
May 10, 2021
08:05AM EDT  TG Therapeutics Q1 Net Loss $90.6 Mln   RTTNews
07:59AM EDT  Recap: TG Therapeutics Q1 Earnings   Benzinga
07:09AM EDT  TG Therapeutics Q1 EPS $(0.69) Misses $(0.49) Estimate, Sales $793.00K Beat $650.00K Estimate   Benzinga
07:00AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the first quarter ending March 31, 2021 and recent company developments, along with a business outlook for 2021.   GlobeNewswire Inc
04:09AM EDT  Earnings Scheduled For May 10, 2021   Benzinga
May 6, 2021
07:30AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, May 10, 2021 at 8:30 AM ET to discuss results for the first quarter 2021 and provide a business outlook for 2021. Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.   GlobeNewswire Inc
Apr 26, 2021
07:30AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Companys Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the B. Riley Securities Neuroscience Conference being held virtually. The fireside chat is scheduled to take place on Wednesday, April 28, 2021 at 9:00 AM ET.   GlobeNewswire Inc
07:00AM EDT  Samsung Biologics and TG Therapeutics Expand Collaboration for the   GlobeNewswire Inc
06:21AM EDT  Samsung Biologics and TG Therapeutics On Sunday Announced The Co.'s Have Expanded The Collaboration For The Large Scale Manufacture of Ublituximab   Benzinga
Apr 25, 2021
09:43PM EDT  Samsung Biologics and TG Therapeutics (TGTX) said that it has expanded a large-scale contract manufacturing deal for the supply of TG Therapeutics' ublituximab, an investigational anti-CD20 monoclonal antibody.   RTTNews
07:11PM EDT  Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale   PR Newswire
Apr 21, 2021
07:04AM EDT  TG Therapeutics Announces Launch Of ULTRA-V Phase 3 Trial Evaluating Triple Combination Of UKONIQ, Ublituximab, And Venetoclax   Benzinga
07:00AM EDT  TG Therapeutics Announces Launch of the ULTRA-V Phase 3 Trial   GlobeNewswire Inc
Apr 20, 2021
10:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2021   Benzinga
06:51AM EDT  Goldman Sachs Initiates Coverage On TG Therapeutics with Neutral Rating, Announces Price Target of $50   Benzinga
Apr 19, 2021
06:58AM EDT  HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $89   Benzinga
Apr 16, 2021
12:28PM EDT  TG Therapeutics shares were trading higher after the company announced the results from its ULTIMATE I & II Phase 3 trials of ublituximab in multiple sclerosis met their primary endpoint. Co. announced results to be presented at the American Academy of Neurology 73rd annual meeting.   Benzinga
07:36AM EDT  TG Therapeutics To Present Results From ULTIMATE I & II Phase 3 Trials Of Ublituximab   Benzinga
07:30AM EDT  Ublituximab demonstrated superiority versus teriflunomide in reducing annualized relapse rates and MRI brain lesions   GlobeNewswire Inc
Apr 15, 2021
04:00PM EDT  TG Therapeutics, Inc.(NASDAQ: TGTX), today announced the schedule of events for the upcoming American Academy of Neurology (AAN) Annual Meeting, being held virtually April 17 22, 2021.   GlobeNewswire Inc
Apr 10, 2021
09:19AM EDT  The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight   Benzinga
Mar 29, 2021
07:43AM EDT  TG Therapeutics Completes Rolling Submission Of Biologics License Application To The FDA For Ublituximab In Combination With UKONIQ As A Treatment For Patients With Chronic Lymphocytic Leukemia   Benzinga
07:42AM EDT  TG Therapeutics Completes Rolling Submission of Biologics License   GlobeNewswire Inc
Mar 9, 2021
09:16AM EST  TG Therapeutics Highlights Publication OF Results From UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy In Patients With Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma In Journal Of Clinical Oncology   Benzinga
07:30AM EST  TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of results from the UNITY-NHL Phase 2b trial evaluating UKONIQ (umbralisib), the Companys inhibitor of PI3k-delta and CK1-epsilon, in patients with relapsed or refractory indolent non-Hodgkin Lymphoma (NHL) in the Journal of Clinical Oncology (JCO).   GlobeNewswire Inc
Mar 4, 2021
04:31PM EST  TG Therapeutics to Present Results from the ULTIMATE I & II Phase   GlobeNewswire Inc
07:30AM EST  TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Companys Executive Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9 10, 2021. The presentation will be accessible for on-demand download beginning on Tuesday, March 9, 2021 at 7:00 AM ET.   GlobeNewswire Inc
Mar 2, 2021
11:50AM EST  HC Wainwright Reiterates Buy Rating, $79 Price Target On TG Therapeutics   Benzinga
07:32AM EST  TG Therapeutics Q4 EPS $(0.71) Misses $(0.58) Estimate, Sales $38.00K Inline   Benzinga
07:00AM EST  TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2020 and recent company developments, along with a business outlook for 2021.   GlobeNewswire Inc
03:40AM EST  Earnings Scheduled For March 2, 2021   Benzinga
Feb 26, 2021
07:30AM EST  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday, March 2, 2021 at 8:30 AM ET to discuss results for the fourth quarter and year-end 2020 and provide a business outlook for 2021. Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.   GlobeNewswire Inc
Feb 23, 2021
07:31AM EST  TG Therapeutics Highlights Publication Of Final Results From Phase 3 GENIUINE Trial Of Ublituximab Plus Ibrutinib in Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia in The Lancet Haematology   Benzinga
07:30AM EST  TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of final results from the Phase 3 GENUINE trial evaluating ublituximab, the Companys investigational glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib, in patients with relapsed or refractory high-risk chronic lymphocytic leukemia (CLL), in The Lancet Haematology.   GlobeNewswire Inc
Feb 9, 2021
11:51AM EST  B. Riley FBR Maintains Buy on TG Therapeutics, Raises Price Target to $95   Benzinga
Feb 8, 2021
01:27PM EST  HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $79   Benzinga
11:45AM EST  TG Therapeutics shares were continuing higher after the FDA approved the company's UKONIQ for the treatment of adult patients with relapsed or refractory marginal zone lymphoma.   Benzinga
Feb 5, 2021
01:55PM EST  UKONIQ is approved for adult patients with relapsed or refractory marginal zone lymphoma after at least one prior anti-CD20 based regimen   GlobeNewswire Inc
12:56PM EST  B. Riley FBR Maintains Buy on TG Therapeutics, Raises Price Target to $90   Benzinga
Jan 31, 2021
05:22AM EST  Attention Biotech Investors: Mark Your Calendar For February PDUFA Dates   Benzinga
Jan 19, 2021
06:22AM EST  HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $78   Benzinga
Jan 15, 2021
07:00AM EST  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Companys Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the B. Riley Securities Oncology Investor Conference being held virtually. The fireside chat is scheduled to take place on Wednesday, January 20, 2021 at 10:00 AM ET.   GlobeNewswire Inc
Jan 14, 2021
07:57AM EST  The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates   Benzinga
Jan 8, 2021
07:00AM EST  TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Companys Executive Chairman and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference, being held virtually. The presentation is scheduled to take place on Tuesday, January 12, 2021 at 2:00 PM ET.   GlobeNewswire Inc
Dec 23, 2020
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
Dec 22, 2020
07:45AM EST  The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes   Benzinga
Dec 17, 2020
08:10AM EST  The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut   Benzinga
Dec 16, 2020
07:15AM EST  The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal   Benzinga
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 14, 2020
07:52PM EST  TG Therapeutics Announces Pricing of Upsized Public Offering of   GlobeNewswire Inc
07:32AM EST  TG Therapeutics Reports $200M Common Stock Offering   Benzinga
07:31AM EST  TG Therapeutics Announces Proposed Public Offering of Common Stock   GlobeNewswire Inc
Dec 11, 2020
08:11AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street   Benzinga
Dec 10, 2020
11:46AM EST  HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $61   Benzinga
09:45AM EST  Hearing Evercore ISI Raises Price Target On TG Therapeutics To New Street-High Target At $70   Benzinga
07:26AM EST  TG Therapeutics Announces Positive Topline Results From ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy For Treatment Of Patients With Multiple Sclerosis; Both Studies Met Primary Endpoint   Benzinga
07:12AM EST  Both studies met their primary endpoint of significantly reducing annualized relapse rate (ARR)(p<0.005 in each study) with ublituximab demonstrating an ARR of <0.10 in each of the studies   GlobeNewswire Inc
Dec 7, 2020
10:15AM EST  UNITY-CLL: U2 significantly improved progression-free survival over obinutuzumabplus chlorambucil (HR=0.54, p<0.0001) as well as ORR (p<0.001) in patients with CLL; with consistent PFS improvement across treatment nave CLL (HR=0.48) and relapsed/refractory CLL (HR=0.60)   GlobeNewswire Inc
10:09AM EST  TG Therapeutics Announces Triple Combination Data Presentations At ASH   Benzinga
10:00AM EST  U2 + Venetoclax: 100% ORR at cycle 12 (n=27), including 41% CR rate, and 96% of patients achieving undetectable MRD in the peripheral blood and 77% achieving undetectable MRD in bone marrow   GlobeNewswire Inc
Dec 6, 2020
08:41AM EST  Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace   Benzinga
Dec 3, 2020
07:00AM EST  TG Therapeutics, Inc. (NASDAQ: TGTX), today recapped the schedule of data presentations at the upcoming 62nd American Society of Hematology (ASH) annual meeting and exposition, to be held virtually December 5 8, 2020.   GlobeNewswire Inc
Dec 2, 2020
07:16AM EST  TG Therapeutics Highlights Publication Of Phase 2 Data Evaluating Umbralisib   Benzinga
07:15AM EST  TG Therapeutics Announces Publication of Phase 2 Data Evaluating   GlobeNewswire Inc
Dec 1, 2020
07:10AM EST  TG Therapeutics Initiates Rolling Submission Of BLA For Ublituximab In Combination With Umbralisib   RTTNews
07:04AM EST  TG Therapeutics Initiates Rolling Submission Of Biologics License Application To FDA For Ublituximab In Combination With Umbralisib As A Treatment For Patients With Chronic Lymphocytic Leukemia   Benzinga
07:00AM EST  TG Therapeutics Initiates Rolling Submission of Biologics License   GlobeNewswire Inc
Nov 30, 2020
07:00AM EST  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Companys Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the 3rd Annual Evercore ISI HealthCONx Conference. The fireside chat is scheduled to take place on Tuesday, December 1, 2020 at 10:05 AM ET.   GlobeNewswire Inc
Nov 13, 2020
07:00AM EST  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Companys Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the Jefferies Virtual London Healthcare Conference. The fireside chat is scheduled to take place on Tuesday, November 17, 2020, at 2:20 PM ET/ 7:20 PM GMT.   GlobeNewswire Inc
Nov 9, 2020
04:46PM EST  TG Therapeutics Q3 EPS $(0.73) Down From $(0.69) YoY, Sales $38.00K, Same YoY   Benzinga
Nov 4, 2020
11:46AM EST  TG Therapeutics Highlights Presentation Of Data For American Society Of Hematology Meeting   Benzinga
11:45AM EST  UNITY-CLL: U2 significantly improved progression-free survival over obinutuzimab plus chlorambucil (HR=0.54, p<0.0001) as well as ORR (p<0.001) in patients with CLL; with consistent PFS improvement across treatment nave CLL (HR=0.48) and relapsed/refractory CLL (HR=0.60)   GlobeNewswire Inc
Nov 2, 2020
07:00AM EST  TG Therapeutics Announces Data Presentations at the Upcoming 62nd   GlobeNewswire Inc
Oct 28, 2020
07:42AM EDT  Cantor Fitzgerald Maintains Overweight on TG Therapeutics, Raises Price Target to $48   Benzinga
Oct 21, 2020
11:12AM EDT  Cramer Shares His Thoughts On FireEye, TG Therapeutics And More   Benzinga
07:41AM EDT  TG Therapeutics: Fast Track Designation Granted By FDA To Ublituximab In Combination With Umbralisib   RTTNews
07:36AM EDT  TG Therapeutics Reports FDA Fast Track Designation For Ublituximab In Combo With Umbralisib For Treatment Of Adults With Chronic Lymphocytic Leukemia   Benzinga
07:30AM EDT  TG Therapeutics Announces Fast Track Designation Granted by the   GlobeNewswire Inc
Oct 2, 2020
03:03PM EDT  TG Therapeutics Option Alert: Nov 20 $35 Calls at the Ask: 481 @ $1.69 vs 865 OI; Earnings 11/10 Before Open [est] Ref=$26.23   Benzinga
Sep 9, 2020
09:17AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its participation at two upcoming virtual investor conferences. Michael S. Weiss, the Companys Executive Chairman and Chief Executive Officer, is scheduled to participate in fireside chats during the following conferences:   GlobeNewswire Inc
Sep 1, 2020
09:47AM EDT  Benzinga's Top Upgrades, Downgrades For September 1, 2020   Benzinga
05:31AM EDT  JP Morgan Initiates Coverage On TG Therapeutics with Overweight Rating, Announces Price Target of $38   Benzinga
Aug 13, 2020
03:30PM EDT  Why TG Therapeutics Is Trading Higher Today   Benzinga
07:17AM EDT  TG Therapeutics Announces FDA Acceptance Of NDA For Umbralisib; Sets PDUFA Goal Date Of June 15, 2021   RTTNews
07:03AM EDT  TG Therapeutics Reports FDA Acceptance Of New Drug Application For Umbralisib As Treatment For Patients With Previously-Treated Marginal Zone Lymphoma, Follicular Lymphoma   Benzinga
07:00AM EDT  TG Therapeutics Announces FDA Acceptance of New Drug Application   GlobeNewswire Inc
Aug 11, 2020
08:44AM EDT  10 Biggest Price Target Changes For Tuesday   Benzinga
06:05AM EDT  HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $38   Benzinga
Aug 10, 2020
07:48AM EDT  TG Therapeutics Q2 EPS $(0.47) Misses $(0.34) Estimate, Sales $38.00K, Same YoY   Benzinga
07:00AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2020 and recent company developments.   GlobeNewswire Inc
04:10AM EDT  Earnings Scheduled For August 10, 2020   Benzinga
Aug 6, 2020
07:30AM EDT  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday August 10, 2020 at 8:30 AM ET to discuss results for the second quarter of 2020 and provide a business outlook for the remainder of the year. Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC